Jnpmedi

About Jnpmedi

Jnpmedi is a life sciences research, development, and commercialization company offering digital solutions for clinical trials. Founded in July 2020 by CEO Kwunho Jeong, the company aims to modernize the clinical trial process through technology. Jeong, who has a background in applied physics and fintech, identified that the core challenge in drug development is data management and launched the company to create more efficient, data-centric solutions. The company's core offering is the 'Maven Clinical Cloud', an end-to-end, cloud-based eClinical solution designed to serve pharmaceutical firms, biotech companies, and medical device manufacturers. This platform provides a suite of tools for managing clinical trial data, including solutions for decentralized clinical trials (DCT), which allow for remote participation. Key features of the Maven platform include electronic data capture (EDC), electronic patient-reported outcomes (eCOA), remote screening and visits, and randomization and trial supply management (RTSM). To ensure data integrity, the platform utilizes blockchain technology to create a secure audit trail, protecting against data tampering. In 2024, Jnpmedi expanded its offerings to include professional services that integrate digital technologies across all stages of a client's business, beyond just the clinical trial phase. Jnpmedi operates on a SaaS-based model, providing its platform and services to clients in various medical fields. The company supports both domestic Korean clients seeking global approval from bodies like the FDA and EMA, as well as overseas companies conducting trials in Korea. It has completed over 300 clinical trials. In addition to its software and services, Jnpmedi has an investment arm that directly invests in Korean biotech firms to help them through early trial phases and strengthen their negotiating position with global pharmaceutical companies. The company has established partnerships with major entities like Naver to incorporate AI technology into its platform and has been recognized as an AWS MSP Partner for its cloud infrastructure management expertise. Since its inception, the company has achieved significant milestones, including securing a Series A funding round of approximately $10.3 million in November 2022, led by Pavilion Capital with participation from all initial seed investors. It has also received government grants, including a 5 billion won grant in 2026 to develop an AI-based 'Clinical OS' that integrates all aspects of clinical trial operations.